VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode

Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.

business card

Not every private biopharmaceutical firm can be Moderna Therapeutics LLC, bringing in hundreds of millions of venture capital dollars in a single fundraising attempt, but startups in the hot immuno-oncology field – like Tioma Therapeutics Inc. and Arcus Biosciences Inc. – continue to raise large Series A and follow-on VC rounds.

Moderna already has accumulated enough money to match the record-breaking $450m venture capital round that it closed in January 2015,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip